Clin Mol Hepatol.
2025 Jan;31(1):e3-e4. 10.3350/cmh.2024.0832.
Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
- Affiliations
-
- 1Department of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China
- KMID: 2563411
- DOI: http://doi.org/10.3350/cmh.2024.0832
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
- Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
- New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
- Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report
- Hepatocellular Carcinoma with Segmental Portal Vein Invasion Exhibiting a Complete Response after Transarterial Radioembolization
